- Clever Leaves is a $284m market-cap producer of pharmaceutical-grade cannabinoids that listed on the Nasdaq via a SPAC acquisition in December 2020.
- The company is developing growing operations in Colombia - where it has 1.8m square foot of cultivation footprint - and Portugal. Both sites have EU-GMP certification.
- Clever Leaves' current focus is on the medical cannabis market, with Germany and the rest of Europe and Brazil key focus areas.
- The company has a nutraceuticals sideline business, Herbal Brands, in the US, providing the necessary distribution network should the US cannabis market open up.
- It's still early days for Clever Leaves but a low market cap and share count provides an opportunity to gain exposure to the cannabis market via an agile, fast-growth company with a first-mover advantage.
For further details see:
Clever Leaves Holdings: A Smart Way To Gain Exposure To Cannabis Market